Cervical cancer is one of the most common cancers in women worldwide, particularly in developing countries. The viral origin of cervical cancer has been proven beyond any reasonable doubt. Persistent infection with certain subsets of human papillomaviruses is recognized as a necessary cause for the development of cervical cancer. Persistence of oncogenic HPVs, immunodeficiency, high HPV viral load and cofactors like smoking, multiple sex partners and poor nutrition predispose to cervical cancer. Prophylactic vaccines using HPV virus-like particles containing capsid protein L1 have shown protection against disease in animals and are currently undergoing clinical trials. Therapeutic vaccines using HPV E6 and E7 proteins are also being investigated for their ability to remove residual infection.
protein also binds to various other cellular proteins like cyclin dependent kinase (cdk) inhibitor p21, possibly leading to loss of cell cycle control. 25 The E7 protein also associates with another group of proteins called histone deacetylases (HDACs) independent of Rb protein and this results in the expression of E2F/DP1 inducible genes. E2F proteins activate expression of various genes necessary for cell cycle progression and DNA replication 26 ( Fig. 2) . Thus the combined effect of these two viral oncoproteins and above mentioned cellular factors contribute to the malignant transformation of the cervical cells.
Epidemiology
Human papillomavirus is transmitted by sexual contact. factor for cervical cancer. Evidence for this is derived from Most Indian studies have reported HPV 16 and 18 as the major genotypes. There is evidence that there are other oncogenic HPV types circulating in our population. In our center, the predominant HPV types detected were HPV 16 and 18 followed by 52, 33, 58, 35, 31, 45 , 51 and 56 (unpublished data).
More recently, naturally occurring HPV variants are gaining importance as viral markers of epidemiology and pathogenesis. Based on sequence analysis of the E6, L1, L2 and long control region, HPV 16 is grouped into five major phylogenetic clusters. They are European (E), Asian (As), Asian-American (AA), African-1(Af1) and African-2 (Af2).
9 A study from our center has shown a higher prevelance (92%) of European (E) variant class of HPV 16 in Indian population.
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Pathogenesis
HPVs infect the basal layers of the cervical squamous epithelium through mild abrasions or trauma. HPV is thought to enter the cell after attaching to cell surface receptor heparan sulphate. 34 The virus life cycle depends on the differentiation of the host squamous epithelium. In the basal layers of the epithelium, the virus genome is episomal and establishes itself at low copy numbers. The early protein E1 in association with E2 is thought to trigger the replication process. At this stage, the expression of the viral oncoproteins E6 and E7 are kept in check by the E2 protein, which acts as a transcriptional repressor. In the terminal layers, the virus switches from theta Cellular protease studies showing a high incidence of HPV infection in human immunodeficiency virus seropositive women. 28 High HPV viral load is a risk factor associated with high stages of cervical disease. 29 Persistence of high-risk types of HPV is another major risk factor in the development of cervical cancer. A higher risk of acquiring HPV was attributed to decreasing age of first sexual intercourse, multiple sexual partners and clinical history of other venereal diseases. 30 High parity was found to increase the risk of infection. 31 Long-term use of oral contraceptives 32 is also a significant cofactor in the development of cervical cancer. However a non-sexual mode of transmission through fomites has also been proposed. 27 Epidemiological evidence also points to an association between cervical cancer and various replication to rolling circle mode of replication, resulting in a high copy number of viral DNA. 35 At this stage, the virus manages to integrate its DNA into the host chromosome. This disrupts the E2 open reading frame leading to excess synthesis of the E6 and E7 oncoproteins. This eventually is thought to lead to malignant transformation of the epithelial cells. Studies from our centre have shown that HPV 16 E6 and E7 transcripts are seen in all cases of invasive cancer but not in cases of cervical intraepithelial neoplasia (CIN) I and II. The presence of episomal E2 DNA in high propotion (52.4%) of patients with invasive carcinoma and the presence of significant variations in the E2 gene suggests that there are alternate mechanisms of E6 and E7 gene expression. 36, 37 Finally, capsid proteins L1 and L2 are synthesized and mature virions are produced. The www.ijmm.org release of HPV virions is thought to be facilitated by the E1 E4 protein.
Laboratory Diagnosis
The high incidence of cervical cancer in developing countries emphasizes the need for proper screening to reduce this global burden. The primary tools for diagnosis of HPV infection are cytology, histology and recently, detection of HPV DNA.
Cytology and histology
The Papanicolou (Pap) smear, introduced by Papanicolau and Traut in 1943, identifies changes in cells of the and uses chemiluminescence to detect the presence of HPV. 43 Recently a prototype version of Hybrid Capture 3 has been released. The hybrid capture 3 was found to be more sensitive and equally specific like its predecessor when compared to the PCR based assays. 44 But this method does not distinguish between the different HPV genotypes.
Most PCR protocols for the detection of genital HPVs use consensus primers GP5/6, 45 The specimen is collected in a preservative solution, debris is HPV is however, weak and studies using HPV virus-like removed thereby aiding clear visualization of the cells. 40 particles (VLPs) have shown that antibodies are detected Colposcopy and colposcopy directed biopsies are done in approximately eight months after incident HPV infection. 54 The patients with abnormal pap smears. Visual inspection is done same study also shows that women who seroconverted were with the naked eye after application of 3% acetic acid solution 5.7 times more likely to progress to HPV associated squamous (VIA).
9 Dysplastic cells appear as acetowhite lesions. Visual intraepithelial neoplasia (SIL) than women who did not inspection with Lugol's iodine (VILI) is another approach seroconvert. These results suggest that in natural infection, where the cervix is viewed with the naked eye after application antibodies to HPV are not protective and serve as a marker of of iodine solution. Normal squamous epithelial cells appear disease progression. Another study showed a seroprevalence brown or almost black in colour whereas abnormal cells appear of 46% in sexually active college women infected with HPV colourless, pale or mustard yellow in colour. 41 HPV cannot be easily cultured in the laboratory. Therefore, molecular methods to detect HPV DNA are been used to confirm the presence to HPV in clinical specimens.
The currently used techniques for HPV DNA detection are the hybrid capture second generation (HC2) assay and polymerase chain reaction (PCR). The hybrid capture assay is the only commercial kit approved by the FDA for the detection of HPV. The hybrid capture assay detects 13 highrisk types (16, 18, 31, 33, 35, 39, 45 ,51,52,56,58,59 and 68) and 5 low risk types (6, 11, 42, 43, 44) . Hybrid Capture 2 assay was found to be a good screening tool for the detection of cervical intraepithelial neoplasia III and invasive cervical cancer. 42 The assay works on a hybridization/ signal amplification principle CIN than in HPV 16 positive patients with (CIN), suggesting a protective role of CTL's in HPV infection. 56 This CTL response was found to be mediated by both CD4-positive and CD8-positive T lymphocytes. 57 Lymphoproliferative responses to a HPV 16 E7 peptide 37-54 were found to be associated with regression of disease and loss of HPV infection suggesting a protective role of cell mediated immune response. Additional therapies to treat HPV infection of the cervix have also been tried. Local application of antiviral agents like cidofovir has been shown to be partly effective against CIN III lesions. 59 Various immunomodulatory agents like being developed for HPV infection, prophylactic vaccine and therapeutic vaccine. Some of the studies on vaccine trials and future candidate vaccines are summarized in Tables 1 and 2 .
Prophylactic vaccines prevent infection by inducing production of neutralizing antibodies. A good prophylactic vaccine should be safe and should induce long-lasting protection. Development of prophylactic vaccines for HPV is hindered by various factors. HPVs are difficult to grow in vitro. Moreover, HPVs are species specific, so vaccine evaluation in animal models is also not possible. Sub-unit vaccines using HPV VLPs, obtained by expressing capsid protein L1and L2 in both prokaryotic and eukaryotic cells are currently being used as candidate vaccines. In early animal models like Screening programs have greatly reduced the incidence of prophylactic vaccines can reduce cervical cancer risk in cervical cancer in the developed world. Prevention programs women who are HPV 16 negative. Recently, a bivalent HPV should comprise of health education and periodic pelvic 16/ 18 virus-like particle vaccine has been shown to be examinations, which may include direct visual inspection efficacious in preventing incident and persistent infections (DVI), VIA, VILI, pap smear and HPV DNA testing. However, with HPV 16 and 18. 67 Quadrivalent vaccines using VLPs made large scale routine screening and treatment for cervical cancer of HPV 6, 11, 16, 18 have been tested for their efficacy in is hard to achieve in a developing country like India. A cost-chimpanzees. The study shows that this vaccine elicits both effective vaccine is therefore needed as an alternative to neutralizing antibodies as well as a transient CTL responses. 68 screening and treatment. There are two types of vaccines Currently phase III trials are being undertaken to prove its 64 these VLPs have shown to be highly been shown to be efficacious in CIN treatment and immunogenic and also shown to elicit high titres of management. In a preliminary study, antioxidant curcumin neutralizing antibodies. An early human trial using HPV 16 caused a down regulation of HPV 18 transcription in Hela cell VLPs produced in insect cells showed high titres of Further studies will establish the clinical efficacy of neutralizing antibodies up to 40 times higher than in a natural curcumin in treatment of cervical cancer.
infection. 65 Another randomized control trial was conducted using HPV 16 VLPs consisting of HPV 16 L1 protein expressed in yeast. This study showed complete protection from disease in the vaccinated group compared to the unvaccinated group. 66 This study has shown that HPV 16 VLPs used as line. Chimeric VLPs have also been developed by fusing non-structural proteins E7 or E2 into L2 protein. 
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Prevention
HPV screening
Conclusions
implicated in causing cervical cancer, which is the most frequently occurring cancer in Indian rural women. India carries a fourth of world's burden of cervical cancer. 75 It is important that health authorities place cervical cancer screening and HPV detection as a high priority in future cancer prevention health strategies. ) .
